PIK3CA and head and neck squamous cell carcinoma: In consistent with our data, abemaciclib and selective PI3K p110α inhibitor combination was superior to single agent treatment in patient-derived xenograft models with PIK3CA mutated head and neck squamous cell carcinoma [42].